Literature DB >> 7946052

Role of Bruton's tyrosine kinase in immunodeficiency.

S Tsukada1, D J Rawlings, O N Witte.   

Abstract

The genetic defect associated with human X-linked agammaglobulinemia and murine X-linked immunodeficiency was recently shown to result from lack of function of a new cytoplasmic tyrosine kinase, called Bruton's tyrosine kinase (Btk). The phenotypes associated with these immunodeficiencies indicate that Btk plays a critical role in B-lymphocyte development. The distinctive protein structure of Btk and preliminary functional studies suggest that Btk may act in a novel manner in a variety of signaling pathways.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7946052     DOI: 10.1016/0952-7915(94)90151-1

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  24 in total

1.  Bruton's tyrosine kinase activity is negatively regulated by Sab, the Btk-SH3 domain-binding protein.

Authors:  T Yamadori; Y Baba; M Matsushita; S Hashimoto; M Kurosaki; T Kurosaki; T Kishimoto; S Tsukada
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

2.  Antiviral immune responses in Itk-deficient mice.

Authors:  M F Bachmann; D R Littman; X C Liao
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 3.  Role of tyrosine kinases in lymphocyte activation: targets for drug intervention.

Authors:  J H Hanke; B A Pollok; P S Changelian
Journal:  Inflamm Res       Date:  1995-09       Impact factor: 4.575

4.  An essential role for Bruton's [corrected] tyrosine kinase in the regulation of B-cell apoptosis.

Authors:  J S Anderson; M Teutsch; Z Dong; H H Wortis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

5.  Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma.

Authors:  Iván Fernández-Vega; Luis M Quirós; Jorge Santos-Juanes; María Pane-Foix; Teresa Marafioti
Journal:  Virchows Arch       Date:  2014-11-30       Impact factor: 4.064

6.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

Review 7.  Cellular and molecular basis of immunodeficiencies: their consequences for the development and induction of the immune response.

Authors:  J Sterzl
Journal:  Folia Microbiol (Praha)       Date:  1998       Impact factor: 2.099

8.  Natural antibodies sustain differentiation and maturation of human dendritic cells.

Authors:  Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Vladimira Donkova-Petrini; Cédric Carbonneil; Namita Misra; Yves Lepelletier; Sandrine Delignat; Sooryanarayana Varambally; Eric Oksenhendler; Yves Lévy; Marianne Debré; Michel D Kazatchkine; Olivier Hermine; Srini V Kaveri
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-20       Impact factor: 11.205

Review 9.  B-lymphocyte tolerance and effector function in immunity and autoimmunity.

Authors:  Wasif N Khan; Jacqueline A Wright; Eden Kleiman; Justin C Boucher; Iris Castro; Emily S Clark
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

10.  CD38 ligation induces tyrosine phosphorylation of Bruton tyrosine kinase and enhanced expression of interleukin 5-receptor alpha chain: synergistic effects with interleukin 5.

Authors:  Y Kikuchi; T Yasue; K Miyake; M Kimoto; K Takatsu
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.